Adial Pharmaceuticals (NASDAQ: ADIL)

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Companys lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Companys landmark ONWARDTM Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Companys proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity...

Drug abuse,drug addiction,alcohol abuse,and alcohol addiction

Adial pharmaceuticals (nasdaq: adil) operates in the Pharmaceutical manufacturing industry.

Adial pharmaceuticals (nasdaq: adil)'s revenue is 1m - 10m

Adial pharmaceuticals (nasdaq: adil) has 11 - 50 employees.